Inspection Record

Nature's Pharmacy & Compounding Center — FDA 483 Findings

US FDAInspected 2015-07-23Published 2024-01-17 9 findingsQuality unit oversightTraining and personnelAseptic processing and sterility assuranceLaboratory and QC controlsStability and storageEquipment and facility

View the regulator's official source The source document is always the basis for judgement.

Findings

1Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing.

2Training and personnel

Clothing of personnel engaged in th e processing of drug products is not appropriate for the duties they perform.

3Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the to produce aseptic conditions.

4Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

5Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.

6Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

7Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

8Stability and storage

There is no written testing program designed to assess the stability characteristics of drug products .

9Equipment and facility

Equipment and utensils are not cleaned, maintained, and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product .

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Nature's Pharmacy & Compounding Center company profile — full history US FDA documents, 2024 Go to Findings search